263 related articles for article (PubMed ID: 10534163)
1. Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility.
Baloch ZW; Abraham S; Roberts S; LiVolsi VA
Hum Pathol; 1999 Oct; 30(10):1166-71. PubMed ID: 10534163
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
3. Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts.
Wallander M; Layfield LJ; Jarboe E; Emerson L; Liu T; Thaker H; Holden J; Tripp S
Appl Immunohistochem Mol Morphol; 2010 May; 18(3):231-5. PubMed ID: 20042852
[TBL] [Abstract][Full Text] [Related]
4. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical diagnosis of papillary thyroid carcinoma.
Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
[TBL] [Abstract][Full Text] [Related]
6. Differential diagnostic significance of HBME-1, CK19 and S100 in various thyroid lesions.
Palo S; Biligi DS
Malays J Pathol; 2017 Apr; 39(1):55-67. PubMed ID: 28413206
[TBL] [Abstract][Full Text] [Related]
7. Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential.
Lamba Saini M; Weynand B; Rahier J; Mourad M; Hamoir M; Marbaix E
Diagn Pathol; 2015 Apr; 10():32. PubMed ID: 25907675
[TBL] [Abstract][Full Text] [Related]
8. Follicular adenoma with papillary architecture: a lesion mimicking papillary thyroid carcinoma.
Mai KT; Landry DC; Thomas J; Burns BF; Commons AS; Yazdi HM; Odell PF
Histopathology; 2001 Jul; 39(1):25-32. PubMed ID: 11454041
[TBL] [Abstract][Full Text] [Related]
9. Keratin subsets in papillary and follicular thyroid lesions. A paraffin section analysis with diagnostic implications.
Miettinen M; Kovatich AJ; Kärkkäinen P
Virchows Arch; 1997 Dec; 431(6):407-13. PubMed ID: 9428928
[TBL] [Abstract][Full Text] [Related]
10. Expression of HBME-1 and CD56 in follicular variant of papillary carcinoma in children: An immunohistochemical study and their diagnostic utility.
Skaria PE; Ahmed AA; Yin H; Nicol K; Reid KJ; Singh V
Pathol Res Pract; 2019 May; 215(5):880-884. PubMed ID: 30711197
[TBL] [Abstract][Full Text] [Related]
11. Cytokeratin subtypes in thyroid tumours: immunohistochemical study with emphasis on the follicular variant of papillary carcinoma.
Cameron BR; Berean KW
J Otolaryngol; 2003 Oct; 32(5):319-22. PubMed ID: 14974863
[TBL] [Abstract][Full Text] [Related]
12. Papillary and follicular neoplasms of the thyroid gland. Differential immunohistochemical staining with high-molecular-weight keratin and involucrin.
Liberman E; Weidner N
Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):42-8. PubMed ID: 10937048
[TBL] [Abstract][Full Text] [Related]
13. Cytokeratin expression profiles in thyroid carcinomas.
Lam KY; Lui MC; Lo CY
Eur J Surg Oncol; 2001 Nov; 27(7):631-5. PubMed ID: 11669590
[TBL] [Abstract][Full Text] [Related]
14. [Expression of cytokeratins and ret in thyroid papillary carcinoma].
Zhou WX; Xiao Y; Liu TH; Luo YF; Cao JL
Zhonghua Bing Li Xue Za Zhi; 2003 Dec; 32(6):530-3. PubMed ID: 14761598
[TBL] [Abstract][Full Text] [Related]
15. HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions.
Sadiq Q; Sekhri R; Dibaba DT; Zhao Q; Agarwal S
World J Surg Oncol; 2021 May; 19(1):143. PubMed ID: 33964951
[TBL] [Abstract][Full Text] [Related]
16. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1.
Casey MB; Lohse CM; Lloyd RV
Endocr Pathol; 2003; 14(1):55-60. PubMed ID: 12746563
[TBL] [Abstract][Full Text] [Related]
17. [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis].
He CN; He L; Cheng JQ; Chen SC; Zhao HF; Zhai JP; Zhang J
Zhonghua Bing Li Xue Za Zhi; 2008 Jan; 37(1):35-9. PubMed ID: 18509983
[TBL] [Abstract][Full Text] [Related]
18. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of CD56 immunohistochemistry in thyroid lesions.
Pyo JS; Kim DH; Yang J
Int J Biol Markers; 2018 May; 33(2):161-167. PubMed ID: 29799356
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic utility of CK19 and galectin-3 in differentiating papillary thyroid carcinoma from nonneoplastic lesions of thyroid.
Prasad PA; Raju K
J Cancer Res Ther; 2022; 18(3):644-649. PubMed ID: 35900535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
